Key facts
- This page summarizes Jason Tardio's Form 4 filing for Ovid Therapeutics Inc. (OVID).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Feb 2024, 18:05.
Jason Tardio - 22 Feb 2024 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- OVID
- Reported as of
- 22 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2024, 18:05:11 UTC
- Prior SEC filing
- 27 Feb 2023
- Next SEC filing
- 12 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Danielle Mann for Jason Tardio by POA
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Tardio filed Form 4 for Ovid Therapeutics Inc. (OVID) on 26 Feb 2024.
Change
- Previous filing in this sequence was filed on 27 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OVID
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +28,125
- Change %
- Price
- $0.000000
- Shares after
- 28,125
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OVID
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +168,750
- Change %
- Price
- $0.000000
- Shares after
- 168,750
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 168,750
- Exercise price
- $3.68
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date.
Footnote F2
Each RSU represents a contingent right to receive one share of Common Stock.
Footnote F3
25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.